share_log

騰盛博藥-B：截至2023年12月31日止年度之年度業績公告

BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023

香港交易所 ·  Mar 22 07:00
Summary by Moomoo AI
騰盛博藥-B（BRII-B）公布截至2023年12月31日止年度業績，銀行存款及現金減少11.3%，研發開支下降8.6%，主因COVID-19項目終止。其他收入增加51.7%，得益於存款利率上升。公司積極推進乙型肝炎病毒項目，並於2024年2月獲得BRII-179全部知識產權，提升生產能力。未來將啟動HBV功能性治癒項目後期臨床試驗，並尋求外部合作推進MDR/XDR、HIV及CNS項目。公司調整執行團隊，優化資源配置，保留穩健現金儲備支持長期運營。
騰盛博藥-B（BRII-B）公布截至2023年12月31日止年度業績，銀行存款及現金減少11.3%，研發開支下降8.6%，主因COVID-19項目終止。其他收入增加51.7%，得益於存款利率上升。公司積極推進乙型肝炎病毒項目，並於2024年2月獲得BRII-179全部知識產權，提升生產能力。未來將啟動HBV功能性治癒項目後期臨床試驗，並尋求外部合作推進MDR/XDR、HIV及CNS項目。公司調整執行團隊，優化資源配置，保留穩健現金儲備支持長期運營。
TENSENG PHARMACEUTICALS - B (BRII-B) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH BANK DEPOSITS AND CASH DOWN 11.3% AND R&D EXPENDITURE DOWN 8.6% DUE TO THE TERMINATION OF COVID-19 PROJECTS. Other income increased 51.7%, driven by higher deposit rates. The company actively promoted the hepatitis B virus project and acquired all intellectual property rights to BRII-179 in February 2024 to increase its production capacity. In the future, post-clinical trials of HBV functional cure projects will be launched and external cooperation will be sought to advance MDR/XDR, HIV and CNS projects. The company realigns its executive team, optimizes resource allocation, maintains a stable cash reserve to support long-term operations.
TENSENG PHARMACEUTICALS - B (BRII-B) ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH BANK DEPOSITS AND CASH DOWN 11.3% AND R&D EXPENDITURE DOWN 8.6% DUE TO THE TERMINATION OF COVID-19 PROJECTS. Other income increased 51.7%, driven by higher deposit rates. The company actively promoted the hepatitis B virus project and acquired all intellectual property rights to BRII-179 in February 2024 to increase its production capacity. In the future, post-clinical trials of HBV functional cure projects will be launched and external cooperation will be sought to advance MDR/XDR, HIV and CNS projects. The company realigns its executive team, optimizes resource allocation, maintains a stable cash reserve to support long-term operations.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more